Christopher Dakhil, MD
Hematology & Oncology · Wichita, KSNPI 1972721348
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Daiichi Sankyo Inc. at 51.5% of the total. Reporting peaked in 2023 at $18,216 and has fallen 77.6% since, to $4,078 in 2025.
Across 1,113 payments — averaging $53.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$30K
- AstraZeneca$4K
- Novartis$3K
- Pfizer$2K
- F. Hoffmann-la Roche AG$2K
- Bristol Myers Squibb$1K
- plus $16K from 54 others
Across 15 payments — averaging $3734.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$54K
- F. Hoffmann-la Roche AG$2K
What the payments were for
- Consulting fees$33,14856%
- Speaking & faculty fees$4,2347%
- Travel & lodging$1,4783%
- Food & beverage$18,71832%
- Education$4691%
- Other$1,0312%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$59,079 in reported general payments places this provider in the 85th percentile of 97 hematology & oncology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 38 | $463,943 |
| IbrancePalbociclib | 25 | $394,314 |
| ImbruvicaIbrutinib | 25 | $384,021 |
| CabometyxCabozantinib S-Malate | 12 | $271,039 |
| VenclextaVenetoclax | 25 | $263,293 |
| Lenalidomide | 12 | $115,410 |
| KisqaliRibociclib Succinate | 14 | $107,890 |
| Pazopanib Hcl | 12 | $97,204 |
| Imatinib Mesylate | 23 | $36,241 |
| EliquisApixaban | 12 | $7,190 |
| Letrozole | 288 | $7,164 |
| Anastrozole | 453 | $4,326 |
| Exemestane | 43 | $3,873 |
| Tamoxifen Citrate | 72 | $1,226 |
| Hydroxyurea | 77 | $1,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $126 | $463,94338 claims |
| PfizerIbrance, Eliquis | $2,325 | $401,50437 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $288 | $384,02125 claims |
| Exelixis Inc.Cabometyx | $137 | $271,03912 claims |
| AbbVieVenclexta | $648 | $263,29325 claims |
| NovartisKisqali | $2,542 | $107,89014 claims |
| Lilly USA, LLCOlanzapine | $112 | $8313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 97 hematology & oncology providers in Kansas.
Other hematology & oncology in Wichita
- Shaker DakhilWichita$579K
- Quoc TruongWichita$539K
- Bassam MattarWichita$221K
- Phu TruongWichita$73K
- Pavan ReddyWichita$65K
- Nassim NabboutWichita$28K
- Jeremy DeutschWichita$28K
- Dennis MooreWichita$26K
- Seth PageWichita$18K
- Marc HoffmannOverland Park$153K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.